van der Maas, A., van den Bemt, B. J., Wolbink, G., van den Hoogen, F. H., van Riel, P. L., & den Broeder, A. A. (2012). Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: Results of an observational cohort study. BioMed Central.
Citação norma Chicagovan der Maas, Aatke, Bart JF van den Bemt, Gertjan Wolbink, Frank HJ van den Hoogen, Piet LCM van Riel, and Alfons A. den Broeder. Low Infliximab Serum Trough Levels and Anti-infliximab Antibodies Are Prevalent in Rheumatoid Arthritis Patients Treated With Infliximab in Daily Clinical Practice: Results of an Observational Cohort Study. BioMed Central, 2012.
Citação norma MLAvan der Maas, Aatke, et al. Low Infliximab Serum Trough Levels and Anti-infliximab Antibodies Are Prevalent in Rheumatoid Arthritis Patients Treated With Infliximab in Daily Clinical Practice: Results of an Observational Cohort Study. BioMed Central, 2012.